Rosella Ciurleo

List of Publications by Year
in descending order

39	1,202	471509 17	377865 34
papers	citations	h-index	g-index

40	40	40	1972
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Evaluation of olfactory dysfunction in neurodegenerative diseases. Journal of the Neurological Sciences, 2012, 323, 16-24.	0.6	167
2	5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases. Bioorganic and Medicinal Chemistry, 2007, 15, 5137-5149.	3.0	104
3	Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. Autoimmunity Reviews, 2020, 19, 102571.	5.8	92
4	5-Arylidene-2-phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors. Bioorganic and Medicinal Chemistry, 2009, 17, 1928-1937.	3.0	79
5	Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). International Journal of Molecular Medicine, 2020, 46, 903-912.	4.0	73
6	Synthesis, induced-fit docking investigations, and in vitro aldose reductase inhibitory activity of non-carboxylic acid containing 2,4-thiazolidinedione derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 5840-5852.	3.0	58
7	1H-MR Spectroscopy in Traumatic Brain Injury. Neurocritical Care, 2011, 14, 127-133.	2.4	55
8	Evaluation of in vitro aldose redutase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3886-3893.	2.2	54
9	Pharmacotherapy for Disorders of Consciousness: Are â€˜Awakeningâ€™ Drugs Really a Possibility?. Drugs, 2013, 73, 1849-1862.	10.9	46
10	Role of statins in the treatment of multiple sclerosis. Pharmacological Research, 2014, 87, 133-143.	7.1	41
11	Magnetic Resonance Spectroscopy: An In Vivo Molecular Imaging Biomarker for Parkinsonâ€™s Disease?. BioMed Research International, 2014, 2014, 1-10.	1.9	38
12	Identification of new non-carboxylic acid containing inhibitors of aldose reductase. Bioorganic and Medicinal Chemistry, 2010, 18, 4049-4055.	3.0	33
13	Emerging Neurological and Psychobiological Aspects of COVID-19 Infection. Brain Sciences, 2020, 10, 852.	2.3	33
14	Synthesis and in vitro evaluation of 5-arylidene-3-hydroxyalkyl-2-phenylimino-4-thiazolidinones with antidegenerative activity on human chondrocyte cultures. Bioorganic and Medicinal Chemistry, 2007, 15, 7618-7625.	3.0	32
15	Structureâ€Based Optimization of Benzoic Acids as Inhibitors of Protein Tyrosine Phosphatase 1B and Low Molecular Weight Protein Tyrosine Phosphatase. ChemMedChem, 2009, 4, 957-962.	3.2	32
16	Detection of Olfactory Dysfunction Using Olfactory Event Related Potentials in Young Patients with Multiple Sclerosis. PLoS ONE, 2014, 9, e103151.	2.5	31
17	Assessment of DuodopaÂ® effects on quality of life of patients with advanced Parkinsonâ€™s disease and their caregivers. Journal of Neurology, 2018, 265, 2005-2014.	3.6	26
18	Discovering common pathogenetic processes between COVID-19 and diabetes mellitus by differential gene expression pattern analysis. Briefings in Bioinformatics, 2021, 22, .	6.5	19

#	Article	IF	Citations
19	Functional Evaluation of Awareness in Vegetative and Minimally Conscious State. Open Neuroimaging Journal, 2017, 11, 17-25.	0.2	17
20	Parosmia and Neurological Disorders: A Neglected Association. Frontiers in Neurology, 2020, 11, 543275.	2.4	16
21	Neurogenic Ejaculatory Disorders: Focus on Current and Future Treatments. Recent Patents on CNS Drug Discovery, 2011, 6, 205-221.	0.9	15
22	Persistent anosmia in a traumatic brain injury patient: Role of orbitofrontal cortex. Brain Injury, 2013, 27, 1715-1718.	1.2	15
23	2/4-Substituted-9-fluorenones and their O-glucosides as potential immunomodulators and anti-herpes simplex virus-2 agents. Part 5. European Journal of Medicinal Chemistry, 2008, 43, 2656-2664.	5.5	14
24	Olfactory dysfunction as a prognostic marker for disability progression in Multiple Sclerosis: An olfactory event related potential study. PLoS ONE, 2018, 13, e0196006.	2.5	13
25	Anxiety, depression, and quality of life in Parkinsonâ€™s disease: the implications of multidisciplinary treatment. Neural Regeneration Research, 2021, 16, 587.	3.0	13
26	Magnetic resonance imaging markers for early diagnosis of Parkinson's disease. Neural Regeneration Research, 2012, 7, 611-9.	3.0	13
27	Effect of the antiepileptic therapy on olfactory disorders associated with mesial temporal sclerosis. Neurocase, 2016, 22, 357-361.	0.6	10
28	Automatic Algorithm for Segmentation of Atherosclerotic Carotid Plaque. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 411-416.	1.6	10
29	The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock	1.0	8
30	Post-traumatic olfactory loss: Psychophysical, electrophysiological and neuroradiological findings in three single case studies. Brain Injury, 2014, 28, 1776-1780.	1.2	7
31	Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. Journal of Neural Transmission, 2015, 122, 799-808.	2.8	7
32	Role of diffusion tensor imaging in the diagnosis and management of post-traumatic anosmia. Brain Injury, 2017, 31, 1964-1968.	1.2	7
33	Striatal topographical organization: Bridging the gap between molecules, connectivity and behavior. European Journal of Histochemistry, 2021, 65, .	1.5	7
34	Acute exacerbation of Hashimoto's thyroiditis in a patient treated with dimethyl fumarate for multiple sclerosis. Medicine (United States), 2019, 98, e15185.	1.0	6
35	Metabolic changes in de novo Parkinsonâ€™s disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study. Neuroscience Letters, 2015, 599, 55-60.	2.1	5
36	Cortical reorganization in multiple sclerosis after intrathecal baclofen therapy. Neurocase, 2014, 20, 225-229.	0.6	3

#	Article	IF	Citations
37	Olfactory event-related potentials in a functionally anosmic patient with arrested hydrocephalus. Journal of International Medical Research, 2019, 47, 1353-1358.	1.0	1
38	The impact of the SARS-COV2 infection on the disorder of consciousness rehabilitation unit. PLoS ONE, 2021, 16, e0253958.	2.5	1
39	Effect of MAO-B Inhibitors on Neurometabolic Profile of Patients Affected by Parkinson Disease: A Proton Magnetic Resonance Spectroscopy Study. Journal of Clinical Medicine, 2022, 11, 1931.	2.4	1